Item 1.01. Entry into a Material Definitive Agreement.

On April 15, 2020, the compensation committee of the board of directors of Immunic, Inc. (the "Company") independently reviewed and approved entering into an employment agreement with the current Chairman of the Board, Duane Nash, MD, JD, MBA (the "Executive Chairman Agreement") and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an "at will" employment relationship pursuant to which Dr. Nash serves as Executive Chairman and contemplated a term that ends on October 15, 2020, which was subsequently extended to April 15, 2021. On April 15, 2021, the Company and Dr. Nash entered into an addendum (the "Agreement") to extend the term of the Executive Chairman Agreement to April 15, 2022.

In connection with the Agreement, the Company made a one-time award to Dr. Nash of an option to purchase 90,000 shares of Company common stock, which will vest monthly commencing on May 15, 2021, and to increase Dr. Nash's monthly base salary to $27,960 from $25,417.

The Agreement is attached as Exhibit 10.1 Current Report on Form 8-K and is incorporated herein by reference.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The information set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 5.02 in its entirety.

Item 9.01. Financial Statements and Exhibits





Exhibit     Description

              Addendum No. 2 to Employment Agreement, dated April 15, 2021,
10.1        between Immunic, Inc. and Duane Nash
104         Cover Page to this Current Report on Form 8-K in Inline XBRL

© Edgar Online, source Glimpses